Table 2.
Baseline characteristics.
| Baseline | n = 40 |
|---|---|
| Female; n [%] | 20 [50.0%] |
| Age at inclusion; median [range], years | 33 [18–68] |
| Disease duration in median years [IQR] | 3.88 [1–14.25] |
| Montreal classification in CD patients | |
| A1 [<16 years] | 5 [12.5%] |
| A2 [17–40 years] A3 [>40 years] |
27 [67.5%] 8 [20.0%] |
| L1 [ileum] | 17 [42.5%] |
| L2 [colon] | 9 [22.5%] |
| L3 [ileocolonic] | 14 [35.0%] |
| B1 [non stricturing, non-penetrating] | 16 [40.0%] |
| B2 [stricturing] | 12 [30.0%] |
| B3 [penetrating] | 12 [30.0%] |
| P [perianal disease] | 11 [27.5%] |
| Previous surgical resection at time of IUS | |
| ICR and ileal re-resections | 15 [37.5%] |
| [Partial] colonic resection | 5 [12.5%] |
| Medication use in medical history | |
| Biologics [infliximab, adalimumab, vedolizumab, ustekinumab] | 15 [37.5%] |
| Immunomodulators [thiopurines/methotrexate] | 20 [50.0%] |
| Corticosteroids | 30 [75.0%] |
| Aminosalicylates | 8 [20.0%] |
| Medication use at inclusion | |
| Corticosteroids | 6 [15.0%] |
| Aminosalicylates | 1 [2.5%] |
| Immunomodulators [thiopurines/methotrexate] | 25 [62.5%] |
| Medication after inclusion | |
| Infliximab | 28 [70.0%] |
| Adalimumab | 12 [30.0%] |
| Clinical and biochemical parameters in median [IQR] | |
| Harvey–Bradshaw Index | 5.0 [3.0–8.0] |
| C-reactive protein in mg/L | 8.25 [2.43–30.08] |
| Haemoglobin in mmol/L | 8.10 [7.40–8.88] |
| Leukocyte count in 109/L | 7.65 [5.95–10.75] |
| Platelet count 1012/L | 340.0 [269.25–405.25] |
| Albumin in g/L | 41.0 [37.75–-44.25] |
| Faecal calprotectin in µg/g | 688.0 [382.0–-1810.50] |
| Intestinal ultrasound parameters | |
| Most severely affected segment | |
| Sigmoid colon | 5 [12.5%] |
| Descending colon | 4 [10.0%] |
| Transverse colon | 2 [5.0%] |
| Ascending colon | 4 [10.0%] |
| Terminal ileum | 25 [62.5%] |
| Bowel wall thickness in mm [median and IQR] | |
| Colour Doppler signal | |
| No signal | 5.21 [4.60–6.84] |
| Single vessel | 1 [2.5%] |
| Stretches within the wall | 5 [12.5%] |
| Stretches in the wall and mesentery | 21 [52.5%] |
| Measurement failed | 10 [25.0%] |
| Loss of stratification | 3 [7.5%] |
| Preserved | |
| Focal loss [< 3 cm] | 19 [47.5%] |
| Extensive loss [≥ 3 cm] | 11 [27.5%] |
| Measurement failed | 7 [17.5%] |
| Presence of inflammatory fat | 3 [7.5%] |
| Not present | 8 [20.0%] |
| Uncertain | 6 [15.0%] |
| Present | 26 [65.0%] |
| Presence of lymph nodes [> 5 mm in shortest axis] | |
| Present | 8 [20.0%] |
| Uncertain | 3 [7.5%] |
| Not present | 29 [72.5%] |
| Motility in terminal ileum [n = 25] | |
| Present | 3 [12.5%] |
| Uncertain | 3 [12.5%] |
| Absent | 19 [79.2%] |
| Colonic haustrations [n = 15] | |
| Loss | 11 [73.3%] |
| Preserved | 4 [26.7%] |
| Endoscopic parameters | |
| Most severely affected segment | |
| Rectum Sigmoid colon |
1 [2.5%] 6 [15.0%] |
| Descending colon | 2 [5.0%] |
| Transverse colon | 2 [5.0%] |
| Ascending colon | 3 [7.5%] |
| Terminal ileum | 26 [65.0%] |
| Total SES-CD score [median and IQR] | 9.0 [5.25–15.00] |
| SES-CD of most affected segment [median and IQR] | 6.50 [3.25–8.00] |
IQR, interquartile range; ICR, ileocecal resection; SES-CD, Simple Endoscopic Score-Crohn’s Disease; IUS, intestinal ultrasound.